| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
EQ
Equillium
|
Jun 02, 2026 | BUY |
Strong Buy
+181.9% avg upside
14 analysts
|
$6.00
96.72% Upside
|
-0.7% |
|
PALI
Palisade Bio
|
Jun 02, 2026 | BUY |
Strong Buy
+1347.1% avg upside
15 analysts
|
$7.00
274.27% Upside
|
-5.4% |
|
IMUX
Immunic
|
May 22, 2026 | BUY |
Strong Buy
+166.0% avg upside
21 analysts
|
$27.00
90.07% Upside
|
+6.2% |
|
AARD
Aardvark Therapeutics, Inc.
|
May 15, 2026 | BUY |
Buy
+386.3% avg upside
12 analysts
|
$7.00
78.17% Upside
|
+0.0% |
|
ALT
Altimmune
|
Mar 06, 2026 | BUY |
Strong Buy
+935.8% avg upside
19 analysts
|
$13.00
381.42% Upside
|
-18.1% |
|
MDGL
Madrigal Pharmaceuticals
|
Dec 11, 2025 | BUY |
Strong Buy
-5.8% avg upside
31 analysts
|
$670.00
32.51% Upside
|
-15.8% |
|
OKYO
OKYO Pharma Limited Sponsored ADR
|
Dec 08, 2025 | BUY |
Strong Buy
+403.1% avg upside
4 analysts
|
$5.00
214.46% Upside
|
-14.7% |
|
CGTX
Cognition Therapeutics
|
Nov 21, 2025 | BUY |
Strong Buy
+305.1% avg upside
9 analysts
|
$3.00
106.87% Upside
|
-13.0% |
|
VERU
Veru
|
Feb 11, 2025 | BUY |
Strong Buy
+568.5% avg upside
10 analysts
|
$50.00
1594.85% Upside
|
-56.6% |
|
LFMD
LifeMD
|
Aug 08, 2024 | BUY |
Strong Buy
+146.3% avg upside
13 analysts
|
$11.00
131.50% Upside
|
+30.6% |
|
CLPT
ClearPoint Neuro
|
May 08, 2024 | BUY |
Strong Buy
+13.7% avg upside
7 analysts
|
$10.00
43.74% Downside
|
+137.9% |
|
KRMD
REPRO-MED Systems
|
May 02, 2024 | BUY |
Strong Buy
+65.0% avg upside
9 analysts
|
$4.00
2.51% Upside
|
+19.8% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.